Showing 701-710 of 2014 results for "".
Journal Club: Dupilumab and Atopic March
https://practicaldermatology.com/programs/Practical-Dermatology-Atopic-Dermatitis-Journal-Club/journal-club-dupilumab-and-atopic-march/32405/Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, and Editorial Board member Peter Lio, MD, discuss recent research indicating a reduced risk of atopic march in pediatric atopic dermatitis patients on dupilumab.Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. ReducedUpdates from CSF 2017
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-updates-from-csf-2017/18371/Dermatologists and core cosmetic physicians shared new insights and reviewed the developments in clinical and cosmetic dermatology at the ninth annual Cosmetic Surgery Forum in Las Vegas. Matthew Zirwas, MD addressed interest in oral supplements to support skin health. Neurotoxin pioneer Nick Lowe,AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and ADermwireTV — Bayer Buys Merck’s OTC Lines, Allergan Rejects Valeant Bid
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-bayer-buys-merck-rsquo-s-otc-lines-allergan-rejects-valeant-bid/19134/Bayer Purchases Merck's OTC Products and Allergan Rebuffs Valeant. This week DermWireTV explores Bayer's growth in the OTC space, including sunscreens, and reports new data on skin cancer mortality. Also in this edition: Neal Bhatia, MD reviews the Noah Worcester Society Annual Meeting.Expanding Indications for Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/expanding-indications-for-neuromodulators-and-fillers-/18626/Emerging science of neuromodulators and fillers are expanding the role of these agents in dermatology practice, according to Dee Anna Glaser, MD. An intriguing area of research, she said, is the use of neuromodulators in the treatment of scars, as well as at the time of surgery for scar prevention.DermWireTV: Minoxidil Shortage; SDPA Conference Coverage; Psoriasis Pipeline Update; Expert Insights on Cabtreo
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-minoxidil-shortage-sdpa-conference-coverage-psoriasis-pipeline-update-expert-insights-on-cabtreo/20225/There's a shortage of available minoxidil in the Washington, DC, area according to newly published data. Study author Adam Friedman, MD, of George Washington University, shares his thoughts on how this shortage--and other drug shortages--might be avoided in the future. At the 21st SDPA Annual ConferConversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiWhy Consider Lasers?
https://practicaldermatology.com/topics/practice-management/why-consider-lasers/18863/Should younger dermatologists add devices to their practice? Laser expert Eric Bernstein, MD talks about the decision to embrace technology and explains how it can mold the future of those who have a passion for lasers and other energy-based devices. Watch other PD Asks videos with Eric BernsteinI knew I wanted to become a dermatologist when...
https://practicaldermatology.com/topics/practice-management/i-knew-i-wanted-to-become-a-dermatologist-when---opefutim/18682/PD Asks: When Yolanda Lenzy, MD was about 13 years old she visited the office of Dr. Lynn McKinley Grant in Washington, DC. It was her first experience with an African American physician, and Dr. Lenzy describes how Dr. McKinley Grant inspired and supported her aspirations. Watch other responses toDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)